Policy and strategy Tirzepatide (Mounjaro®) for the management of obesity and overweight (WHC/2025/018) Letter to health boards, general practitioners and pharmacies about medication for weight management. Part of: Health circulars: 2024 to 2027 and Medicines and medical devices (Sub-topic) First published: 8 May 2025 Last updated: 9 May 2025 Documents Tirzepatide (Mounjaro®) for the management of obesity and overweight (WHC/2025/018) Tirzepatide (Mounjaro®) for the management of obesity and overweight (WHC/2025/018) , HTML HTML
